Panacea Acquisition Corp. (PANA) to Combine with Nuvation Bio in $1.3Bn Deal

Oct 21, 2020 INTEL by Nicholas Alan Clayton

Biotech firm Nuvation Bio announced this morning that it had entered into a definitive business combination agreement with Panacea Acquisition Corp. (NYSE:PANA) for an enterprise value of about $1.3 billion. New York-based Nuvation Bio is developing six novel treatments for a variety of cancer types. The combined company is to be remain listed on the
Read More

To access this post, you must purchase a Monthly or Yearly SPACInsider Subscription, or log in if you're a member.

Panacea Acquisition Corp. (PANA) to Combine with Nuvation Bio in $1.3Bn Deal

Panacea Acquisition Corp. (PANA) to Combine with Nuvation Bio in $1.3Bn Deal

ByNicholas Alan Clayton